Navigation Links
Resonant Medical Appoints New Vice President of Global Sales
Date:9/10/2007

alizes and corrects daily changes in tumor position, shape and size, thus ushering in a new era of 3D ultrasound (U/S) multimodality radiotherapy treatment planning and image guidance. Installed in CT-Sim rooms, Restitu U/S-Sim(TM) allows for better definition of planning tumor volumes with its patented IMPLICIT REGISTRATION(TM) technology that automatically fuses 3D U/S to CT data. With U/S-Sim, multimodality treatment planning has now been made possible and affordable for all clinics, with or without PET or MRI. Installed in treatment rooms, Restitu U/S-Guide(TM) allows for highly accurate patient position verification and alignment, with its proprietary MUTUAL REFERENCING(TM) technology that uses assisted segmentation for efficient and robust intramodality 3D U/S image-guidance.


'/>"/>
SOURCE Resonant Medical inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Ayurvedic Therapies Cashing In On Medical Tourism
4. Robots craft medical history
5. NBE to conduct test for medical students from abroad
6. Air pollution combined with greater medical needs
7. Indian Nationals with Foreign Medical Degrees can now practice in India
8. Children! Protecting them from medical mistakes
9. More information sought by patients on medical errors
10. SARS necessitates medical masks
11. Meditation Works Medically
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 1Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 2Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2